SPECIALIZED PGM OF RESEARCH EXCELLENCE/PROSTATE CANCER

通过这项申请，贝勒医学院回应了RFA：CA- 91-35，前列腺卓越研究(孢子)专业计划 癌症。在外部认可的调查人员的领导下 贝勒资助了他们目前在前列腺癌方面的研究 组织了一支能力很强的科学家团队，进行创新 前列腺癌的生物学研究及其预防、诊断 以及治疗这种疾病的患者。科学计划将 通过新的机制解决翻译研究问题 “工作组”。这些多学科的临床和基础团队 科学家-一些研究项目的首席研究员，其他核心 董事，一些计划未来的试点项目，其他成员 内部咨询委员会--因为他们的共同利益而走到一起 在四个焦点区域之一，并组成临床标记物， 化学预防、分子机制和内分泌工作组。 我们的战略将是专注于前列腺癌的早期进展 从潜伏期到临床期。具体的调查要点 是：(1)区分稳定和不稳定形式的潜伏癌症，以及 (2)确定进展率所涉及的生物学因素。 具体的干预点是：(1)潜伏癌：使用标记物 区分稳定和不稳定的潜伏癌，发展医学 预防病情从稳定进展到不稳定的治疗(化学预防) 潜伏性癌症，以及(2)早期临床癌症：使用新的标记物 预测进展速度，并根据风险应用适当的治疗 这种疾病的危害。 该方案中包含的具体项目和核心内容都已开发完成 经过我们的科学咨询委员会的深入审查，该委员会由Dr。 伯特·奥马利，负责这项研究的科学质量 程序。我们明智地分配了预算，以反映我们的灵活性 重点战略：37%分配给8个研究项目，35%分配给5个 支持研究和试点项目的核心设施，17%的响应 通过发展迅速抓住新的创新研究机会 研究计划和11%用于职业发展，以帮助培养新干部 研究人员能够扩大翻译研究的领域 前列腺癌。 有非常多的多民族患者人口，并有相当大的 在空间、资金和人员方面承诺的机构资源，以及 一支多学科的团队，拥有公认的成功记录，贝勒 建议通过以下方式显著扩大其对前列腺癌的研究 孢子将进入前列腺癌的翻译研究领域 新的临床和基础研究人员与现有的 在这里，调查人员将提供重要的新信息，对我们的 前列腺癌的战略方法。我们努力的目的是 最终降低由此导致的发病率和死亡率 毁灭性的疾病。

Through this application, Baylor College of Medicine responds to RFA: CA- 91-35, Specialized Programs Of Research Excellence (SPORE) in Prostate Cancer. Under the leadership of investigators recognized by the externally sponsored support for their current research in prostate cancer, Baylor has organized a team of highly competent scientists to perform innovative research in the biology of prostate cancer and the prevention, diagnosis and treatment of patients with this disease. The scientific program will address translational research issues through the novel mechanism of "working groups". These multidisciplinary teams of clinical and basic scientists - some principal investigators of research projects, others core directors, some planning future pilot projects, others members of the Internal Advisory Committee - were drawn together by their common interest in one of four focal areas and compose the Clinical Markers, Chemoprevention, Molecular Mechanisms and Endocrine Working Groups. Our strategy will be to focus on the early progression of prostate cancer from its latent to clinical forms. The specific POINTS OF INVESTIGATION are: (1) differentiate stable from unstable forms of latent cancer, and (2) determine the biological factors involved in the rate of progression. The specific POINTS OF INTERVENTION are: (1) Latent Cancer: Use markers to distinguish stable from unstable latent cancer, and develop medical therapy (chemoprevention) to prevent progression from stable to unstable latent cancer, and (2) Early Stage Clinical Cancer: Use new markers to predict the rate of progression and apply therapy appropriate to the risk of the disease. The specific projects and cores included in this program were developed after intensive review by our Scientific Advisory Committee, chaired by Dr. Bert O'Malley, which is responsible for the quality of the science in this program. We have judiciously allocated our budget to reflect our flexible yet focused strategy: 37% assigned among 8 Research Projects, 35% to 5 Core Facilities to support the research and pilot projects, 17% to respond rapidly to new innovative research opportunities through the Developmental Research Program and 11% to Career Development to help produce a new cadre of investigators able to expand the field of translational research in prostate cancer. With a very large and multi-ethnic patient population and with considerable institutional resources committed in space, funds, and personnel, and with a multidisciplinary team with a proven track record of success, Baylor proposes to expand markedly its studies of prostate cancer through this SPORE to bring to the field of translational research in prostate cancer new clinical and basic investigators who, together with the established investigators here, will provide essential new information valuable in our strategic approach to prostate cancer. The purpose of our efforts is ultimately to reduce the incidence and the mortality rate from this devastating disease.